Arch Biopartners Inc.
$5,407,235.00
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
SIF Stream 1- R&D
FY 2020-2021
Canada
This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.